The anticoagulant rivaroxaban is safer than and works as well as standard dual therapy for blood clots of the lung, according to a 4,833-patient study presented at a cardiology meeting. A lower percentage of patients taking rivaroxaban experienced major and minor bleeding compared with those who took the combination therapy.

Full Story:

Related Summaries